immatics biotechnologies GmbH
MAGEB2 BINDING CONSTRUCTS

Last updated:

Abstract:

The present invention relates to antibody constructs comprising a domain which binds to a MAGEB2 peptide complexed with an HLA and optionally, another domain which binds to CD3. Moreover, the invention provides polynucleotides encoding the antibody constructs, vectors comprising said polynucleotides and host cells transformed or transfected with said polynucleotides or vectors. Furthermore, the invention provides processes for producing the antibody constructs of the invention, medical uses of said antibody constructs, and kits comprising said antibody constructs.

Status:
Application
Type:

Utility

Filling date:

18 May 2021

Issue date:

20 Jan 2022